Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | IDE | P14735 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | HLCS | P50747 | 6/20 | 0.61 |
| ▸ | CA12 | O43570 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | CA2 | P00918 | 5/20 | 0.51 |
| ▸ | CA9 | Q16790 | 5/20 | 0.51 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28119479 | 0.93 | TDP1 (0.81) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21114407 | 0.93 | TDP1 (0.81) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28283183 | 0.93 | TDP1 (0.81) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21176811 | 0.93 | TDP1 (0.81) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22265330 | 0.92 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28516361 | 0.91 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL4407437 | 0.90 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22290232 | 0.89 | TDP1 (0.82) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28516340 | 0.89 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20473406 | 0.88 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| US-20250075170-A1 | TARGETED MUTAGENESIS IN SPIRULINA | Lumen Bioscience, Inc. | 2025-03-06 | — | — | US | disclosed |
| US-12065638-B2 | Targeted mutagenesis in spirulina | Lumen Bioscience, Inc. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-3191581-B9 | TARGETED MUTAGENESIS IN SPIRULINA | LUMEN BIOSCIENCE INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3191581-B1 | TARGETED MUTAGENESIS IN SPIRULINA | LUMEN BIOSCIENCE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3940057-A1 | TARGETED MUTAGENESIS IN SPIRULINA | Lumen Bioscience, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113717913-A | Targeted mutagenesis in spirulina | 流明生物科学公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-106687578-B | Targeted mutagenesis in spirulina | 流明生物科学公司 | 2021-09-24 | — | — | CN | disclosed |
| US-20210047610-A1 | CYANOBACTERIA HAVING IMPROVED PHOTOSYNTHETIC ACTIVITY | Lumen Bioscience, Inc. | 2021-02-18 | — | — | US | disclosed |
| US-10760045-B2 | Cyanobacteria having improved photosynthetic activity | Lumen Bioscience, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20100184169-A1 | Modified Photosynthetic Microorganisms With Reduced Glycogen and Their Use in Producing Carbon-Based Products | TARGETED GROWTH, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010075440-A1 | MODIFIED PHOTOSYNTHETIC MICROORGANISMS WITH REDUCED GLYCOGEN AND THEIR USE IN PRODUCING CARBON-BASED PRODUCTS | TARGETED GROWTH, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010048568-A1 | MODIFIED PHOTOSYNTHETIC MICROORGANISMS FOR PRODUCING TRIGLYCERIDES | TARGETED GROWTH, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100081178-A1 | MODIFIED PHOTOSYNTHETIC MICROORGANISMS FOR PRODUCING TRIGLYCERIDES | TARGETED GROWTH, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| EP-2150265-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | Neuera Pharmaceuticals, Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1960003-A2 | TARGETED NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING | General Electric Company (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070140974-A1 | Targeted nanoparticles for magnetic resonance imaging | GENERAL ELECTRIC COMPANY (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007069040-A2 | TARGETED NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING | GENERAL ELECTRIC COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | TDP1 4155/4885MEN1 3493/4885ABL1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.